SUD Validation Data Supplement Will Have 90-Day Review Target – FDA
This article was originally published in The Gray Sheet
Executive Summary
Submission of validation data for reprocessed single-use devices that have already received 510(k) clearance will not result in additional user fees, FDA clarifies in a reuse guidance posted on the CDRH website July 3
You may also be interested in...
Biopsy Forceps Review Request Prompts Category Change For Nine SUDs
Reprocessed single-use non-electric biopsy forceps will no longer be considered 510(k)-exempt devices, meaning that reprocessors will need to file premarket notification and validation data with FDA by July 30, 2004
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.